For example, Pollard and Alonzo demonstrated that adding sorafenib to standard chemotherapy significantly improved event-free survival (EFS) and reduced relapse risk in FLT3/ITD+ pediatric AML patients (26). Here, FLT3 is linked to acute myeloid leukemia.